UPDATE : Friday, August 7, 2020
HOME Pharma
Breast cancer therapy Ibrance likely to get insurance benefit
  • By Nam Doo-hyun
  • Published 2017.07.07 14:26
  • Updated 2017.07.11 11:30
  • comments 0

Pfizer’s breast cancer therapy Palbociclib, better known as Ibrance, is likely to receive insurance coverage.

The Pharmaceutical Benefits Committee of Health Insurance Review & Assessment Service (HIRA)건강보험심사평가원 Thursday concluded the Ibrance Cap is appropriate to receive insurance benefits.

If Palbociclib passes a drug price negotiation between the pharmaceutical company and National Health Insurance Service(NHIS)국민건강보험공단, it can get insurance coverage when people take the drug with Letrozole (a product name: Femara Tab.) as the first endocrine therapy.

Before announcing the result of the assessment, a group of breast cancer patients has called for the government and Pfizer to provide insurance benefits for Palbociclib.

The committee also made a similar judgment for melanoma treatment Mekinist Tab. made by Novartis when taken together with Dabrafenib (a product name: Tafinlar Cap).

Meanwhile, lung cancer therapy made by Roche Korea한국로슈, Alecensa (compound: alectinib), diabetics therapy made by Novo Nordisk Pharma노보노디스크, Victoza Pen Inj, and hepatitis B treatment made by Ildong Pharmaceutical일동제약, Besivo Tab., received conditional insurance coverage.

The committee evaluated six substances submitted by five pharmaceutical companies.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Nam Doo-hyun
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top